Skip to main contentSkip to navigation
Sirius Investors

KRYS Stock: Krystal Biotech, Inc. Stock Price, Analysis & Insights

Get live KRYS stock price $312.50, comprehensive Krystal Biotech, Inc. stock analysis, charts, news, and expert forecast. Real-time KRYS stock data and investment insights.

312.50
0.89%Today
KRYSKrystal Biotech, Inc. • NASDAQ Global Market • Healthcare
Market Cap
9.21B
Volume
186.04K
52W High
320.32
52W Low
127.99

Loading chart data...

Krystal Biotech, Inc. (KRYS) Overview

Krystal Biotech, Inc. (KRYS) is a publicly traded company in the Healthcare sector , specifically within the Biotechnology industry . As of the latest trading session, KRYS trades at $312.50 with a market capitalization of 9.21B . Over the past 52 weeks, KRYS has traded between $127.99 and $320.32 , with the current price positioned at approximately 96% of this range . The stock currently trade...

Key Takeaways

  • Operates in the Healthcare sector (Biotechnology)
  • Market cap: 9.21B
  • Current price: $312.50
  • 52-week range: $127.99 - $320.32
  • P/E ratio: 41.78

Investment Score

Annual (latest period)
Unavailable

A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is curr...

Company Information

CEO
Krish S. Krishnan
Sector
Healthcare
Industry
Biotechnology
Employees
275

Contact Information

Address
2100 Wharton Street
Country
US

Investment Analysis & Business Insights

Healthcare
Biotechnology

Investment Highlights

Strong presence in the Healthcare sector with established market position

Growth-oriented company with premium valuation (P/E: 41.8)

Lower volatility stock (Beta: 0.53) may provide portfolio stability

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for Krystal Biotech, Inc. shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for Krystal Biotech, Inc.
  • Investors should consider how Krystal Biotech, Inc. fits within their overall portfolio allocation
  • Premium valuation (P/E: 41.8) requires strong growth to justify

Market Cap

9.21B

P/E Ratio (TTM)

41.78

Beta

0.53

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.